Progen gets strategic advice
Wednesday, 27 August, 2008
Progen Pharmaceuticals [ASX: PGL] has appointed a new group of corporate advisors to help guide the company's development.
The company has commissioned the services of the independent corporate advisory firm Beerworth and Partners (BPL).
BPL has been hired to assess Progen's operations and develop strategic options to be reviewed by Progen's Board of directors.
The advisory firm will also provide general corporate advice and assist the board as required.
According to Progen, the decision to hire advisors was made when the directors realised the company's strong cash position after terminating the PI88 Phase III Pathway study in liver cancer.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
